Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission

Manufacturing Work Addressing FDA CMC Information Requests Substantially CompletedNDA Resubmission Expected Between December 2026 and January 2027KANSAS CITY, Kan., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. NASDAQ:CING, a biopharmaceutical company utilizing its proprietary Precision Timed Re…